Product Reports Resources Pricing Login Book a demo

Karius

Biotech & Life Sciences · Redwood City, United States · Founded 2014

Karius is a life sciences startup that operates in the medical diagnostics market, specifically focusing on infectious diseases. The company's primary offering is the Karius Test, a liquid biopsy that can detect over 1,000 pathogens from a single blood sample. This test is non-invasive and quick, making it a valuable tool for clinicians treating vulnerable hospitalized patients. It helps avoid the need for multiple invasive, low-yield diagnostic tests that can delay treatment. The Karius Test uses advanced genomics and artificial intelligence (AI) to detect microbial cell-free DNA (mcfDNA), which are tiny fragments of DNA from microbes that are circulating in the bloodstream. This technology allows the company to provide unique insights into the pathogens causing infections. The company's business model revolves around selling these diagnostic tests to healthcare providers. By providing a faster, non-invasive alternative to traditional diagnostic methods, Karius has the potential to save lives and reduce healthcare costs. The company's proprietary machine learning algorithms analyze complex genomic data in real time, and their reference genome databases are constantly updated as more data becomes available. This continuous learning and improvement is a key part of the company's strategy to stay at the forefront of infectious disease diagnostics. In summary, Karius is a life sciences company that uses advanced genomics and AI to provide rapid, non-invasive diagnostic tests for infectious diseases, serving healthcare providers and their patients. Keywords: Life Sciences, Medical Diagnostics, Infectious Diseases, Non-Invasive Testing, Genomics, Artificial Intelligence, Microbial Cell-Free DNA, Healthcare Providers, Machine Learning, Real-Time Analysis.

Investors

18 investors on Karius's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 9 investors entered at this stage
Tencent
Khosla Ventures
S28 Capital
Pacific 8 Ventures
SoftBank Vision Fund
SoftBank
General Catalyst
HBM Healthcare Investments
HBM Partners
Series B+ 6 investors entered at this stage
Oxford Finance
5AM Ventures
Gilde Healthcare
Seventure Partners
Blue Water Life Science
Waycross Ventures

Global footprint

Where Karius has talent and traffic

Workforce by country
3 countries with
team presence
🇺🇸 United States98.7%
🇩🇪 Germany0.7%
🇨🇦 Canada0.7%
3 countries shown

Talent graph

The shape of Karius's talent

Dealroom maps Karius's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

21 team members profilednamed & role-tagged by Dealroom
207 employeestotal headcount
6 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Karius's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Karius

An AI-synthesized read of the highest-engagement posts about Karius on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Karius on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.